We evaluated a rate coiorimetric method (Beckman) for measuring total protein in cerebrospinal fluid. The automated instrument we used was Beckman's ASmA.
The total-protein module (which is used for both serum and spinal-fluid protein) contains the total-protein board assembly as the electronic front end of the channel. The assembly depends on an external photodetector to supply its primary input signal, and provides a regulated voltage to use with an external incandescent source lamp. The primary output signal is a voltage that is proportional to the total protein concentration in a fluid sample. The rate of change, with respect to time, of the light absorbance of the sample (at 545 nm) is proportional to the protein concentration. The dA/dt signal is coarsely scaled to provide the output signal, which isanalyzed by digital techniques in a master computer sectionthat isnot part of the assembly board.
The analog circuits consist of a current-to-voltage converter, pre-amplifier, log converter, buffer amplifier, multiplexer, differentiating output amplifier, and voltage regulator. The input signal to the pre-amplifier is a very low-level current generated by a vacuum photodiode located in the sample cell. A small beam of white light from the source lamp passes first through the sample cell and then through an interference filter (545 nm) before striking the detector. The output current from the detector is an analog of the light-transmitting property of the sample in the cell. The current, about 100 nA, is first converted to a percent transmittance (T) voltage signal in the pre-amplifier.
The logarithm of the signal is converted into a low-level analog for absorbance.
Each decade change in percent T generates about 0.065 V, which needs to be amplified. The buffer stage increases the signal to about 6.5 V. The absorbance signal is differentiated in the final output stage where a capacitor converts changes in input voltage (dA/dt) into a low-level current, which is amplified by the final stage. The multiplexer input can be programmed by the external computer to select a high gain, to detect the low concentration of protein found in cerebrospinal fluid.
The instrument used in the comparison study was also a discrete analyzer, the aca III (Dii (4) . We followed the supplier's instrument instructions: 1000 L of biuret reagent is delivered to the measuring cuvet by the pumping system, after which the automatic probe samples and delivers 100 iL of cerebrospinal fluid. A typical reaction is shown in Figure 1 . The injection of sample into the cuvet takes 3 s, and there is a 6-s period ("blind rate") when no readings are taken, to avoid any aberrant signals owing to perturbation. Therefore the rate signal is monitored 9s after injection and again 20.5 s after injection. The rate signal is verified at this time by a check of the absorbance to be certain that exhaustion of reagents has not occurred. The absorbance check also detects any exceeding of the specified spectral limitations.
Results

Analytical Variables
Precision. We tested within-day and between-day precision (CV) by using four pools prepared by diluting "Ortho Normal Unassayed Serum" (Ortho Diagnostics, Raritan, NJ 08869) with distilled water. The batch we used in this experiment is our usual serum control pool; we have established its totalprotein content to be 62 g/L. The serum was diluted to give nominal concentrations of 1200, 600, 300, and 150 mg/L. Within-day precision was tested by assaying 20 replicates per run on four or five separate days. We assessed between-run precision by using single samples of the 150,300,600, and 1200 mgIL controls in 20 separate runs over 10 days. Typical within-day data were: mean 123.5 (SD 13.8) mgfL, CV 11.23%; mean 276.0 (SD 16.7), CV 6.04%; mean 561.5 (SD 15.3) mg/L, CV 2.73%; and mean 1167 (SD 11.3) mg/L, CV 0.967%. Between-run precision data were: mean 127.0 (SD 19.0) mg/L, CV 15.2%; mean 262.5 (SD 17.5) mg/L, CV 6.67%; mean 562.5 (SD 19.4) mg/L, CV 3.45%; and mean 1160.8 (SD 27.0) mgfL, CV 2.33%.
Linearity.
For linearity studies, we measured eight albumin solutions with concentrations ranging from 125 to 7500 mg/L. Four separate experiments were carried out in triplicate on four separate days. Deviation from linearity ranged from -1.5 to +1.7%. We determined the lowest and highest limits of detectability of both systems (aca and ASTRA). The test solution was the "Ortho Normal Control" pool, suitably diluted with water. The lower and upper limits of the analytical response of the aca were: 100 (SD 15) mg/L, CV 15%, and 2500 (SD 48) mg/L, CV 1.9%. The ASTRA lower and upper limits were: 120 (SD 16) mg/L, CV 13.3%, and 7500 (SD 78) mgfL, CV 1.04%.
Carryover studies. We performed carryover studies according to the method of Passey et al. (5) . On one carousel, a sample with a high concentration was assayed in triplicate followed by a low-concentration sample in triplicate, followed by a high-concentration sample in triplicate, and so on. In a typical carousel run a sample of 4000 mg/L (triplicate) was followed by a sample of 300 mg/L (triplicate), followed by 4000 mg/L in triplicate, followed by water in triplicate, and the 4000 mg/L sample in triplicate. Using such a scheme, we tested a full carousel (38 positions) and found no carryover. Expanding the study to include higher concentrations (10 000 mg/L) still showed no carryover to the 300 mg/L samples or in water.
When we included a normal human serum [protein concentration of 62 gIL, followed by a sample of 300 mgIL, followed by a normal serum, followed by water, and so on (all in trip- Interferences. We examined the influence of hemoglobin and bilirubin on the rate biuret assay for spinal fluid protein.
We first assayed pure hemoglobin solutions to assess the apparent concentrations as if they were samples of spinal fluid Finally, we tested the ability of the system to distinguish extreme variations in albumin/globulin ratios. Aqueous solutions of pure human albumin and globulin fractions were prepared to a target value of 1000mg of total protein per liter. Unlike the aca spinal fluid assay, the ASTRA rate biuret reaction showed no deviation from the expected concentration, in spite of radical changes of the albumin/globulin ratio ( Figure 2 ).
Clinical Samples
We used 131 fresh samples in a patient-correlation study, carried out over a period of three weeks. All of the samples were assayed in duplicate, and the variation between dupli- The cross calibrator experiments showed minimum discrepancies between the two instruments. The modest bias (about 7%) demonstrated in the assay of patients' samples can in part be explained by these discrepancies and would suggest that the calibrator assignments are at slight variance. The differences are, however, not clinically significant.
The novel detection system, the analysis time (one sample per minute), the automated aspects of the technique, and the satisfactory comparison with an estabished method all make
